Pricing
  1. JP-listed companies
  2. SUSMED, Inc.
  3. Financials
  4. EBITDA

SUSMED, Inc. (4263)

Market cap
¥16.6B
P/E ratio
Susmed develops digital therapeutic apps and IT platforms that help pharmaceutical companies and healthcare providers conduct clinical trials and analyze medical data more efficiently.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Jun 30, 2025-292-18.80%
Jun 30, 2024-359+739.40%
Jun 30, 2023-43-81.17%
Jun 30, 2022-227-31.86%
Jun 30, 2021-333+107.61%
Jun 30, 2020-161

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat